阿普米司特治疗银屑病及银屑病关节炎患者焦虑抑郁风险研究
基于美国MarketScan数据库的两项队列研究,比较阿普米司特与其他系统治疗在银屑病及银屑病关节炎患者中引发需治疗的焦虑、抑郁及混合焦虑抑郁的风险。结果显示银屑病队列中各治疗组发生率相似,系统性皮质激素单用组最高;银屑病关节炎队列中阿普米司特单用组焦虑发生率略高,但抑郁及混合焦虑抑郁与其他非皮质激素系统药物相似。
要点
- 银屑病患者中阿普米司特与其他非皮质激素系统治疗的焦虑抑郁发生率相似。
- 银屑病关节炎患者中阿普米司特单用组焦虑发生率略高于其他治疗。
- 两队列中系统性皮质激素单用者的焦虑抑郁发生率均较高。
核心结论
- 银屑病患者使用阿普米司特的焦虑抑郁发生率与其他非皮质激素系统治疗相似。
- 银屑病关节炎患者使用阿普米司特的抑郁及混合焦虑抑郁发生率与其他非皮质激素系统药物相似,但焦虑发生率略高。
研究设计与样本
- 在美国MarketScan数据库中进行两项独立队列研究,分别纳入银屑病和银屑病关节炎患者。
- 暴露组为阿普米司特、TNF抑制剂生物制剂、IL-17/23/12/23抑制剂生物制剂、传统DMARDs或系统性皮质激素。
- 队列进入日期为2014年3月21日后首次使用研究药物的日期。
主要发现
- 银屑病队列中,阿普米司特单用组需治疗的焦虑、抑郁及混合焦虑抑郁的发病率(95%CI)分别为9.2(6.6-12.5)、4.6(2.8-7.1)和4.6(2.8-7.1)/1000患者年。
- 银屑病队列中各暴露类别结局发生率相似,系统性皮质激素单用组最高。
- 银屑病关节炎队列中,阿普米司特单用组焦虑发生率最高;抑郁及混合焦虑抑郁发生率与其他治疗相似。
- 两队列中系统性皮质激素使用者的各结局发生率均较高。
关键数值与推荐
- 需治疗的病例定义为诊断抑郁和/或焦虑后30天内开具抗抑郁/抗焦虑药物处方。
- 计算每1000患者年的发病率及发病率比(95%CI)。
临床怎么用
- 临床中对银屑病及银屑病关节炎患者使用阿普米司特时,应关注焦虑症状,尤其银屑病关节炎患者。
- 系统性皮质激素单用与较高的焦虑抑郁发生率相关,应谨慎评估精神共病风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anxiety and depression are common among psoriasis and psoriatic arthritis (PsA) patients, but rates may differ by treatment. OBJECTIVE: To quantify the risk of incident treated anxiety, depression and mixed anxiety + depression in users of apremilast compared with users of other treatments for psoriasis and PsA. METHODS: We conducted two separate cohort studies of psoriasis and PsA patients treated with apremilast, tumour necrosis factor inhibitor biologics, interleukin-17, -23 or -12/23 inhibitor biologics, conventional DMARDs or systemic corticosteroids in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. We identified cases who had a depression and/or anxiety diagnosis with a prescription for antidepressant/antianxiety medication within 30 days of the diagnosis code. We calculated incidence rates (IRs) and incidence rate ratios with 95% confidence intervals (CIs) for treated anxiety, treated depression and treated anxiety + depression per 1000 patient-years (PY) among patients. RESULTS: Among the psoriasis cohort, IRs for each outcome were similar between exposure categories and highest among users of systemic corticosteroids alone. IRs (95% CI) for apremilast alone were 9.2 (6.6-12.5), 4.6 (2.8-7.1) and 4.6 (2.8-7.1) per 1000 PY for treated anxiety, treated depression and treated anxiety + depression, respectively. In the PsA cohort, the rate of anxiety was highest among users of apremilast alone; rates of depression and anxiety + depression were similar for apremilast compared with other PsA treatments. IRs for each outcome were also high for users of corticosteroids in both the psoriasis and PsA cohorts. CONCLUSIONS: Among patients with psoriasis, users of apremilast had similar rates of anxiety and depression as users of other non-corticosteroid systemic psoriasis treatments. Among PsA patients, users of apremilast had similar rates of depression and anxiety + depression compared with users of other systemic non-corticosteroid PsA drugs; however, the rate of anxiety was slightly higher.
引用
- Vasilakis-Scaramozza C, Persson R, Hagberg KW, et al. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database. J Eur Acad Dermatol Venereol. 2020. PMID: 31981426. doi:10.1111/jdv.16231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。